Rio Piedras, Puerto Rico Clinical Trials

A listing of Rio Piedras, Puerto Rico clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

estrogen receptor
inflammatory breast cancer
cyclophosphamide
HER2
hormone therapy
UPR Comprehensive Cancer Center ( Site 6200)
 (4.4 away) Contact site
  • 188 views
  • 10 Jun, 2021
  • +285 other locations
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

lung carcinoma
carboplatin/paclitaxel
durvalumab
EGFR
gemcitabine
Research Site
 (2.3 away) Contact site
  • 251 views
  • 02 Jun, 2021
  • +308 other locations
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine …

Hospital Oncologico, Puerto Rico Medical Center
 (4.4 away) Contact site
  • 20 views
  • 03 Feb, 2021
  • +121 other locations
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or …

nephropathy
renal disease
renal failure
chronic kidney disease
Puerto Rico Clinical and Translational Research Consortium (PRCTRC)
 (4.4 away) Contact site
  • 133 views
  • 26 Jan, 2021
  • +36 other locations
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

mirikizumab
plaque psoriasis
GCM Medical Group, PSC - Hato Rey Site
 (2.3 away) Contact site
  • 717 views
  • 28 May, 2021
  • +352 other locations
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. …

body mass index
cardiovascular disease
overweight or obesity
Novo Nordisk Investigational Site
 (2.2 away) Contact site
  • 7712 views
  • 02 Jun, 2021
  • +1164 other locations
A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients

A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. 100 patients will be enrolled in a 100 mg open-label arm.

fatty liver
fibrosis
liver disease
dyslipidemia
fibroscan
Fundacion de Investigacion de Diego
 (6.8 away) Contact site
  • 237 views
  • 24 Jan, 2021
  • +67 other locations
The Object of This Study is to Evaluate the Efficacy Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone

psychosis
antidepressant therapy
antidepressants
adjunctive treatment
depressive episode
INSPIRA Clinical research
 (2.6 away) Contact site
  • 709 views
  • 02 Jun, 2021
  • +113 other locations
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune …

endometrioid adenocarcinoma
brachytherapy
absolute neutrophil count
oophorectomy
serous adenocarcinoma
Centro Comprensivo de Cancer de UPR
 (1.8 away) Contact site
  • 71 views
  • 10 Jun, 2021
  • +172 other locations
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance …

vinorelbine
cancer chemotherapy
vincristine
cancer
actinomycin
San Jorge Children's Hospital
 (4.1 away) Contact site
  • 292 views
  • 12 Jun, 2021
  • +290 other locations